🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMASH / Liver DiseaseHepatic steatosis grading on ultrasound — what worked for you? Page 2

Hepatic steatosis grading on ultrasound — what worked for you?

marcus_mpls Sun, Oct 12, 2025 at 12:06 AM 9 replies 1,276 viewsPage 2 of 2
VendorMark
Senior Member
3,456
14,567
Jan 2024
Texas
Online
Oct 12, 2025 at 3:10 AM#6
Dr.ObesityMed said:
NASH/MAFLD therapeutic landscape and liver and MASH: GLP-1 agonists are emerging as potential first-line NASH therapy.

Liver ultrasound comparison for liver and MASH: my hepatologist ordered serial ultrasounds to track NAFLD regression.

Baseline: "Moderate hepatic steatosis, liver span 17.2cm, echogenic texture consistent with fat infiltration"
Month 8: "Mild steatosis, liver span 15.8cm, improved echogenicity"
Month 14: "Minimal to no steatosis, normal liver span 14.5cm, normal echotexture"

My liver literally shrank and de-fattened. The ultrasound tech said she's seen this pattern increasingly in GLP-1 patients and it's remarkable how consistently the fatty liver resolves.

16 11DebRD_ATL, KristenIndy, MarkLI_maint and 13 others
Reply Quote Save Share Report
Dr.PathRoch
Member
456
2,123
Jun 2024
Rochester, MN
Oct 12, 2025 at 4:21 AM#7
marcus_mpls said:
ALT was mildly raised at baseline, normalised at month five, and I now have no idea whether anything happened to the fibrosis that actually matters.

ATTAIN trial (survodutide) context for liver and MASH: survodutide, a GLP-1/glucagon dual agonist, showed -18.7% body weight at 46 weeks in the Phase 3 ATTAIN trial. NASH resolution was achieved in ~60% of patients[1].

This is relevant to liver and MASH because survodutide's glucagon agonism specifically targets hepatic lipid metabolism — making it potentially the best-in-class agent for NASH/MAFLD comorbid with obesity.

References:
[1] Sanyal AJ, et al. N Engl J Med. 2024.
15 10InsuranceTom, WendyG_ATL, SaraMom3 and 12 others
Reply Quote Save Share Report
pat_auckland
Member
345
1,567
Jun 2024
Auckland, NZ
Oct 12, 2025 at 5:32 AM#8
VendorMark said:
Liver ultrasound comparison for liver and MASH: my hepatologist ordered serial ultrasounds to track NAFLD regression.

Adding the part of the answer the thread has not reached. The version of this that has an answer is narrower than the version being asked. Narrow it and it becomes tractable; leave it broad and the thread will produce nine confident and incompatible replies.

Ask again with the specifics and you will get a better answer than this one.

14 9LarryQC_SD, wanda_boise, NurseAsh_DET and 11 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
mia_MS2
New Member
8
23
Jun 2026
Ann Arbor, MI
Oct 12, 2025 at 6:43 AM#9

Following on from DataDave — and this may be the naive question:

Was that from a primary source or from a summary of one?

13 8steve_okc, dave_SLC, FDA_TrackerJim and 10 others
Reply Quote Save Share Report
marcus_mpls
Member
234
1,123
Nov 2024
Minneapolis, MN
Oct 12, 2025 at 12:24 PM#10

Reporting back.

Update, and it is the boring outcome: nothing was wrong. The measurement I was reading had moved less than its own week-to-week variation, which somebody said upthread and I did not believe.

3 1mona_PHX, andrew_nyc, Dr.EndoEP
Reply Quote Save Share Report

Similar Threads

Survodutide MASH Phase 2b — histological improvement data9 replies
Semaglutide and MASH — liver fat reduction quantification13 replies
Non-invasive MASH biomarkers — FibroScan, ELF, FIB-4 on GLP-110 replies
ALT normalization rates on GLP-1 — pooled trial data20 replies
GLP-1 hepatoprotection — direct vs indirect mechanisms16 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register